Cytokinetics, Incorporated

Cytokinetics, Incorporatedverified

CYTK

Price:

$48.53

Market Cap:

$5.73B

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activa...[Read more]

Industry

Biotechnology

IPO Date

2004-04-30

Stock Exchange

NASDAQ

Ticker

CYTK

The Enterprise Value as of December 2024 (TTM) for Cytokinetics, Incorporated (CYTK) is 6.47B

According to Cytokinetics, Incorporated’s latest financial reports and current stock price. The company's current Enterprise Value is 6.47B. This represents a change of -15.21% compared to the average of 7.63B of the last 4 quarters.

Cytokinetics, Incorporated (CYTK) Historical Enterprise Value (quarterly & annually)

How has CYTK Enterprise Value performed in the past?

The mean historical Enterprise Value of Cytokinetics, Incorporated over the last ten years is 2.10B. The current 6.47B Enterprise Value has changed 30.73% with respect to the historical average. Over the past ten years (40 quarters), CYTK's Enterprise Value was at its highest in in the December 2023 quarter at 8.91B. The Enterprise Value was at its lowest in in the September 2015 quarter at 231.43M.

Quarterly (TTM)
Annual

Average

2.10B

Median

578.16M

Minimum

265.81M

Maximum

8.70B

Cytokinetics, Incorporated (CYTK) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Cytokinetics, Incorporated Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 162.16%

Maximum Annual Enterprise Value = 8.70B

Minimum Annual Increase = -30.64%

Minimum Annual Enterprise Value = 265.81M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
20238.70B81.30%
20224.80B31.07%
20213.66B162.16%
20201.40B96.59%
2019710.51M106.49%
2018344.09M11.28%
2017309.21M-30.64%
2016445.81M25.95%
2015353.96M33.16%
2014265.81M69.17%

Cytokinetics, Incorporated (CYTK) Average Enterprise Value

How has CYTK Enterprise Value performed in the past?

The current Enterprise Value of Cytokinetics, Incorporated (CYTK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

5.72B

5-year avg

3.85B

10-year avg

2.10B

Cytokinetics, Incorporated (CYTK) Enterprise Value vs. Peers

How is CYTK’s Enterprise Value compared to its peers?

Cytokinetics, Incorporated’s Enterprise Value is greater than DICE Therapeutics, Inc. (1.82B), greater than Edgewise Therapeutics, Inc. (2.76B), less than Karuna Therapeutics, Inc. (12.43B), greater than Dyne Therapeutics, Inc. (1.93B), greater than Stoke Therapeutics, Inc. (451.87M), greater than Pliant Therapeutics, Inc. (801.51M), less than Revolution Medicines, Inc. (7.98B), greater than Relay Therapeutics, Inc. (605.49M), greater than Black Diamond Therapeutics, Inc. (123.50M), greater than Arvinas, Inc. (1.20B), greater than Terns Pharmaceuticals, Inc. (223.81M), greater than Amylyx Pharmaceuticals, Inc. (204.92M), greater than Acumen Pharmaceuticals, Inc. (104.35M), greater than Inozyme Pharma, Inc. (210.44M), greater than X4 Pharmaceuticals, Inc. (79.71M), greater than Blueprint Medicines Corporation (6.13B),

Build a custom stock screener for Cytokinetics, Incorporated (CYTK) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cytokinetics, Incorporated using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cytokinetics, Incorporated (CYTK) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cytokinetics, Incorporated or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Cytokinetics, Incorporated's Enterprise Value?

What is the highest Enterprise Value for Cytokinetics, Incorporated (CYTK)?

What is the 3-year average Enterprise Value for Cytokinetics, Incorporated (CYTK)?

What is the 5-year average Enterprise Value for Cytokinetics, Incorporated (CYTK)?

How does the current Enterprise Value for Cytokinetics, Incorporated (CYTK) compare to its historical average?